FDA to streamline approvals of generic biologic drugs

2026 is shaping up to be a make-or-break year for #BigPharma. The U.S. Food and Drug Administration is lining up major drug decisions for Novo Nordisk, Eli Lilly, Merck, and Takeda — rulings that could reshape #cancer care, #obesity treatment, pricing, and patient access. Approvals or delays here won’t just move stocks — they’ll change #medicine itself. #FDA #DrugApprovals #PharmaNews #HealthPolicy #Biotech #Oncology #RareDisease #MetabolicHealth #AIinMedicine #HealthcareMarkets #BreakingNews #F